Unicycive Therapeutics, Inc. 8-K

What Happened

• On June 5, 2026, Unicycive Therapeutics, Inc. filed an 8‑K stating it entered into Amendment No. 2 to its Sales Agreement with Guggenheim Securities, LLC to raise the maximum aggregate amount of Common Stock that may be sold through its at‑the‑market (ATM) program to $150,000,000.
• The company also filed a Shelf Registration Statement on Form S‑3 on June 5, 2026 that includes a sales agreement prospectus to register $50,000,000 of Common Stock for sale in the ATM Offering.

Key Details

• Amendment No. 2 dated June 5, 2026 increases the ATM offering capacity from the prior $100,000,000 limit to $150,000,000.
• The original Sales Agreement was entered November 13, 2024 and previously amended on November 14, 2025.
• The Form S‑3 filed June 5, 2026 registers $50,000,000 of Common Stock for sale under the ATM; the stock’s par value is $0.001 per share.
• Guggenheim Securities, LLC is the sales agent for the ATM program.

Why It Matters

• Raising the ATM capacity gives Unicycive more flexibility to raise capital quickly by selling shares into the market as needed, which can help fund operations or development programs.
• Any sales under the ATM will dilute existing shareholders; investors should monitor future prospectus supplements or press releases for actual sale amounts and timing.
• The 8‑K and registration filing are procedural steps to permit sales; the filing itself is not an offer to sell shares and sales will occur only if and when the company chooses to sell under the registered program.